De challenging and re challenging
Reading File
Finding Sources
Finding Sources
Searching the Web
dechallenge rechallenge adverse drug reaction causality assessment pharmacovigilance
Finding Sources
Finding Sources
Reading File
Here is a thorough explanation of dechallenge and rechallenge in clinical pharmacovigilance:
Dechallenge and Rechallenge
These two concepts are core to causality assessment - the process of determining whether a drug caused a particular adverse event in a patient.
Dechallenge
Definition: The withdrawal (discontinuation) of a suspected drug after an adverse drug reaction (ADR) has occurred, to observe whether the reaction resolves.
Interpreting the result:
| Result | Meaning | Implication |
|---|---|---|
| Positive dechallenge | ADR improves or disappears after drug withdrawal | Causal relationship with the drug is more likely |
| Negative dechallenge | ADR continues despite drug withdrawal | Causal relationship is less likely |
| Partial dechallenge | Only the dose is reduced (not fully stopped) to see if the ADR decreases | Used when full withdrawal is not feasible |
Clinical note (drug-induced liver injury context): Dechallenge should be accompanied by discernible, progressive improvement within days to weeks of stopping the suspected drug. Some agents (e.g., ketoconazole, amiodarone, troglitazone) are exceptions - clinical recovery may be delayed for months even after successful dechallenge. Failure of jaundice to resolve in a suspected drug reaction often indicates an alternative diagnosis. - Sleisenger and Fordtran's Gastrointestinal and Liver Disease
Rechallenge
Definition: The deliberate or inadvertent re-administration of the suspected drug after a dechallenge has been performed, to confirm causality by observing whether the ADR recurs.
Interpreting the result:
| Result | Meaning | Implication |
|---|---|---|
| Positive rechallenge | ADR reappears after reintroduction | Strongest evidence of drug causality |
| Negative rechallenge | ADR does not recur | Weakens causal link |
| Partial rechallenge | Gradual re-titration of the drug | Used when full dose reintroduction is dangerous |
Ethical caution: Rechallenge is the "gold standard" test for drug causation but is rarely used in practice because it carries real risk. In drug-induced liver disease, one study reported severe hepatocellular injury in 18% of rechallenged patients, and 2 died. Therefore, rechallenge should only be performed:
- With fully informed written patient consent
- Preferably with institutional ethics committee approval
- When clinical benefit justifies the risk (e.g., no safer alternative drug exists)
- Sleisenger and Fordtran's GI and Liver Disease, p.1668
Role in Causality Assessment Scales
Dechallenge and rechallenge outcomes are scored in every major causality assessment tool:
1. WHO-UMC Scale - uses 4 criteria:
- Time sequence between drug use and ADR
- Absence of other competing causes
- Response to dechallenge (drug withdrawal)
- Response to rechallenge (drug re-administration)
- A reaction is classified as "Certain" only when ALL four criteria are met, including a positive rechallenge
2. Naranjo Scale - assigns numeric scores to dechallenge and rechallenge outcomes among 10 questions; the total score classifies an ADR as definite, probable, possible, or doubtful
3. Karch and Lasagna Scale - explicitly incorporates dechallenge (resolution after stopping) and rechallenge (recurrence on restarting) among its four main criteria
Summary of Causality Categories (WHO-UMC)
| Category | Time sequence | Other causes ruled out | Dechallenge | Rechallenge |
|---|---|---|---|---|
| Certain | Yes | Yes | Positive | Positive |
| Probable | Yes | Yes | Positive | Not done |
| Possible | Yes | No | No | No |
| Unlikely | No | No | No | No |
Clinical Examples
- Isotretinoin and depression: Case reports with positive dechallenge and positive rechallenge have been documented, suggesting a causal link between isotretinoin and psychiatric adverse effects (depression). - Fitzpatrick's Dermatology; Andrews' Diseases of the Skin
- Drug-induced liver injury (DILI): Rechallenge is theoretically the definitive test for DILI but avoided in practice due to risk of severe hepatic injury on reexposure. - Sleisenger and Fordtran's GI and Liver Disease
- Diplopia/ptosis from drugs: Positive dechallenge and rechallenge cases have been reported in neurology to confirm drug-induced ocular muscle effects. - Localization in Clinical Neurology
In summary: A positive dechallenge suggests the drug is responsible; a positive rechallenge confirms it. Together, they provide the strongest pharmacovigilance evidence for drug causality - but rechallenge must be weighed carefully against patient safety.
This is a shared conversation. Sign in to Orris to start your own chat.